Product Information
FENOFIBRATE 130 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.6795 per EA under NDC 63304044490. Its NADAC has been published 576 times since Aug 12, 2015.
FDA first approved this application on Oct 31, 2014.
Strength
130 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
63304044490
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA201748FDA Approved
10/31/2014
On Market Since
3/2/2015
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 130 MG CAPSULE has been published 576 times since Aug 12, 2015, and over the history we have for it it has declined 84.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6795 per EA |
|---|---|
| All-time high | $4.4034 (Nov 11, 2015) |
| All-time low | $0.5104 (Sep 20, 2023) |
| 52-week high | $0.8173 |
| 52-week low | $0.6427 |
| Median price | $1.7017 |
| Average price | $1.8070 |
| Largest weekly change | -52.7% (Aug 23, 2023) |
| Weeks tracked | 576 |
| Tracking since | Aug 12, 2015 |
1W
N/A
1M
N/A
3M
+3.8%
6M
-4.8%
1Y
-12.5%
3Y
+33.1%
5Y
-58.9%
All
-84.3%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 130 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 130 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $0.6795 per EA (NDC 63304044490), effective Aug 19, 2026.
How has the price of FENOFIBRATE 130 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 130 MG CAPSULE has declined 84.3%. It has been tracked across 576 weekly CMS publications since Aug 12, 2015.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 130 MG CAPSULE?
Since Aug 12, 2015, the NADAC for FENOFIBRATE 130 MG CAPSULE has ranged from a low of $0.5104 (Sep 20, 2023) to a high of $4.4034 (Nov 11, 2015), with a median of $1.7017 per EA.
Are there cheaper alternatives to FENOFIBRATE 130 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRATE 130 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRATE 130 MG CAPSULE?
FENOFIBRATE 130 MG CAPSULE (NDC 63304044490) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.